We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Demand for the corticosteroid dexamethasone has skyrocketed in the days since the University of Oxford published trial results suggesting the drug could be a game-changer for treating severely ill COVID-19 patients, hospital data shows. Read More
Gilead Sciences has signed four more non-exclusive licensing agreements with generic drugmakers to make remdesivir available to COVID-19 patients in low-income countries. Read More
Corvidia’s shareholders will receive an upfront payment of $725 million and will be eligible for future payments that could total $2.1 billion. Read More
The European Investment Bank is making available up to $113 million in financing for BioNTech’s BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity for it in Europe. Read More
Fujifilm said it plans to invest $928 million to double production capacity at its biologics manufacturing facility in Denmark to supply bulk drug substances for future COVID-19 therapies and other products. Read More
Partly in response to the COVID-19 pandemic, HHS is partnering with a Boston-based drugmaker to create a domestic supply chain that doesn’t rely on foreign sources for active pharmaceutical ingredients. Read More